% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Obi:178415,
      author       = {N. Obi and A. Y. Jung$^*$ and T. Maurer and M. Huebner and
                      T. Johnson$^*$ and S. Behrens$^*$ and S. Jaskulski$^*$ and
                      H. Becher and J. Chang-Claude$^*$},
      title        = {{A}ssociation of circulating leptin, adiponectin, and
                      resistin concentrations with long-term breast cancer
                      prognosis in a {G}erman patient cohort.},
      journal      = {Scientific reports},
      volume       = {11},
      number       = {1},
      issn         = {2045-2322},
      address      = {[London]},
      publisher    = {Macmillan Publishers Limited, part of Springer Nature},
      reportid     = {DKFZ-2022-00042},
      pages        = {23526},
      year         = {2021},
      note         = {#LA:C020#},
      abstract     = {Adipokines including leptin, adiponectin and resistin have
                      been linked to risk of obesity-related cancers potentially
                      through low-grade chronic inflammation pathways. We aimed to
                      assess the role of post-diagnosis circulating adipokines on
                      long-term prognosis in a prospective breast cancer cohort.
                      Adipokines were measured in blood collected at baseline
                      shortly after diagnosis (2002-2005) and at follow-up (2009)
                      from 3112 breast cancer patients enrolled in the
                      population-based MARIE study. Half of the patients had
                      measurements at both time-points. All-cause mortality,
                      breast cancer specific mortality and recurrences were
                      ascertained up to June 2015 (11 years median follow-up).
                      Associations with time-varying adipokine concentrations
                      overall and stratified by estrogen and progesterone receptor
                      (ERPR) were evaluated using adjusted proportional hazard
                      regression. At baseline (n = 2700) and follow-up (n = 2027),
                      median concentrations for leptin, adiponectin and resistin
                      were 4.6 and 2.7 ng/ml, 24.4 and 30.0 mg/l, 15.4 and
                      26.2 ng/ml, respectively. After adjustment, there was no
                      evidence for associations between adipokines and any outcome
                      overall. In ERPR negative tumors, highest vs. lowest
                      quintile of adiponectin was significantly associated with
                      increased breast cancer specific mortality (HR 2.51,
                      $95\%CI$ 1.07-5.92). Overall, post-diagnosis adipokines were
                      not associated with long-term outcomes after breast cancer.
                      In patients with ERPR negative tumors, higher concentrations
                      of adiponectin may be associated with increased breast
                      cancer specific mortality and warrant further
                      investigation.},
      cin          = {C020},
      ddc          = {600},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34876619},
      pmc          = {pmc:PMC8651788},
      doi          = {10.1038/s41598-021-02958-w},
      url          = {https://inrepo02.dkfz.de/record/178415},
}